Skip to main content
Journal cover image

Systemic Bevacizumab for Treatment of Respiratory Papillomatosis: International Consensus Statement.

Publication ,  Journal Article
Sidell, DR; Balakrishnan, K; Best, SR; Zur, K; Buckingham, J; De Alarcon, A; Baroody, FM; Bock, JM; Boss, EF; Bower, CM; Campisi, P; Chen, SF ...
Published in: Laryngoscope
June 2021

OBJECTIVES/HYPOTHESIS: The purpose of this study is to develop consensus on key points that would support the use of systemic bevacizumab for the treatment of recurrent respiratory papillomatosis (RRP), and to provide preliminary guidance surrounding the use of this treatment modality. STUDY DESIGN: Delphi method-based survey series. METHODS: A multidisciplinary, multi-institutional panel of physicians with experience using systemic bevacizumab for the treatment of RRP was established. The Delphi method was used to identify and obtain consensus on characteristics associated with systemic bevacizumab use across five domains: 1) patient characteristics; 2) disease characteristics; 3) treating center characteristics; 4) prior treatment characteristics; and 5) prior work-up. RESULTS: The international panel was composed of 70 experts from 12 countries, representing pediatric and adult otolaryngology, hematology/oncology, infectious diseases, pediatric surgery, family medicine, and epidemiology. A total of 189 items were identified, of which consensus was achieved on Patient Characteristics (9), Disease Characteristics (10), Treatment Center Characteristics (22), and Prior Workup Characteristics (18). CONCLUSION: This consensus statement provides a useful starting point for clinicians and centers hoping to offer systemic bevacizumab for RRP and may serve as a framework to assess the components of practices and centers currently using this therapy. We hope to provide a strategy to offer the treatment and also to provide a springboard for bevacizumab's use in combination with other RRP treatment protocols. Standardized delivery systems may facilitate research efforts and provide dosing regimens to help shape best-practice applications of systemic bevacizumab for patients with early-onset or less-severe disease phenotypes. LEVEL OF EVIDENCE: 5 Laryngoscope, 131:E1941-E1949, 2021.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Laryngoscope

DOI

EISSN

1531-4995

Publication Date

June 2021

Volume

131

Issue

6

Start / End Page

E1941 / E1949

Location

United States

Related Subject Headings

  • Respiratory Tract Infections
  • Papillomavirus Infections
  • Otorhinolaryngology
  • Internationality
  • Humans
  • Delphi Technique
  • Consensus
  • Bevacizumab
  • Angiogenesis Inhibitors
  • 3202 Clinical sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Sidell, D. R., Balakrishnan, K., Best, S. R., Zur, K., Buckingham, J., De Alarcon, A., … Derkay, C. S. (2021). Systemic Bevacizumab for Treatment of Respiratory Papillomatosis: International Consensus Statement. Laryngoscope, 131(6), E1941–E1949. https://doi.org/10.1002/lary.29343
Sidell, Douglas R., Karthik Balakrishnan, Simon R. Best, Karen Zur, Julia Buckingham, Alessandro De Alarcon, Fuad M. Baroody, et al. “Systemic Bevacizumab for Treatment of Respiratory Papillomatosis: International Consensus Statement.Laryngoscope 131, no. 6 (June 2021): E1941–49. https://doi.org/10.1002/lary.29343.
Sidell DR, Balakrishnan K, Best SR, Zur K, Buckingham J, De Alarcon A, et al. Systemic Bevacizumab for Treatment of Respiratory Papillomatosis: International Consensus Statement. Laryngoscope. 2021 Jun;131(6):E1941–9.
Sidell, Douglas R., et al. “Systemic Bevacizumab for Treatment of Respiratory Papillomatosis: International Consensus Statement.Laryngoscope, vol. 131, no. 6, June 2021, pp. E1941–49. Pubmed, doi:10.1002/lary.29343.
Sidell DR, Balakrishnan K, Best SR, Zur K, Buckingham J, De Alarcon A, Baroody FM, Bock JM, Boss EF, Bower CM, Campisi P, Chen SF, Clarke JM, Clarke KD, Cocciaglia A, Cotton RT, Cuestas G, Davis KL, DeFago VH, Dikkers FG, Dossans I, Florez W, Fox E, Friedman AD, Grant N, Hamdi O, Hogikyan ND, Johnson K, Johnson LB, Johnson RF, Kelly P, Klein AM, Lawlor CM, Leboulanger N, Levy AG, Lam D, Licameli GR, Long S, Lott DG, Manrique D, McMurray JS, Meister KD, Messner AH, Mohr M, Mudd P, Mortelliti AJ, Novakovic D, Ongkasuwan J, Peer S, Piersiala K, Prager JD, Pransky SM, Preciado D, Raynor T, Rinkel RNPM, Rodriguez H, Rodríguez VP, Russell J, Scatolini ML, Scheffler P, Smith DF, Smith LP, Smith ME, Smith RJH, Sorom A, Steinberg A, Stith JA, Thompson D, Thompson JW, Varela P, White DR, Wineland AM, Yang CJ, Zdanski CJ, Derkay CS. Systemic Bevacizumab for Treatment of Respiratory Papillomatosis: International Consensus Statement. Laryngoscope. 2021 Jun;131(6):E1941–E1949.
Journal cover image

Published In

Laryngoscope

DOI

EISSN

1531-4995

Publication Date

June 2021

Volume

131

Issue

6

Start / End Page

E1941 / E1949

Location

United States

Related Subject Headings

  • Respiratory Tract Infections
  • Papillomavirus Infections
  • Otorhinolaryngology
  • Internationality
  • Humans
  • Delphi Technique
  • Consensus
  • Bevacizumab
  • Angiogenesis Inhibitors
  • 3202 Clinical sciences